Targeting protein kinases in central nervous system disorders - Wikidata - wikimedia - TriplyDB

Targeting protein kinases in central nervous system disorders

Targeting protein kinases in central nervous system disorders

http://www.wikidata.org/entity/Q33671660

about

Ten things you should know about protein kinases: IUPHAR Review 14 Melanoma brain metastases: an unmet challenge in the era of active therapy The unstable repeats--three evolving faces of neurological disease A Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in Cardiomyocytes Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction Phenocopy--a strategy to qualify chemical compounds during hit-to-lead and/or lead optimization Selective inhibition of the kinase DYRK1A by targeting its folding process Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor.Small-molecule anticonvulsant agents with potent in vitro neuroprotection and favorable drug-like properties.Beneficial compaction of spinal cord lesion by migrating astrocytes through glycogen synthase kinase-3 inhibition.CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.Prevention of tumor seeding during needle biopsy by chemotherapeutic-releasing gelatin sticks.Activation loop dynamics determine the different catalytic efficiencies of B cell- and T cell-specific tec kinases.Molecular targeting of glioblastoma: Drug discovery and therapies Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors.Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.Kinase inhibitor scaffolds against neurodegenerative diseases from a Southern Australian ascidian, Didemnum sp.Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.MEK/ERK signaling pathway is required for enterovirus 71 replication in immature dendritic cells Screening Dyrk1A inhibitors by MALDI-QqQ mass spectrometry: systematic comparison to established radiometric, luminescence, and LC-UV-MS assays.Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ)Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin.Phenotypic assays to identify agents that induce reactive gliosis: a counter-screen to prioritize compounds for preclinical animal studies Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Δ7 SMA KO Mouse Model of Spinal Muscular Atrophy.Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.Mechanisms of regulation of oligodendrocyte development by p38 mitogen-activated protein kinase Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model.The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS.Disease-Specific Differentiation Between Drugs and Non-Drugs Using Principal Component Analysis of Their Molecular Descriptor Space.Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer.Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.Molecular Docking and In Silico ADMET Study Reveals Acylguanidine 7a as a Potential Inhibitor of β-Secretase Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis Natural products as a source of Alzheimer's drug leads.Death associated protein kinases: molecular structure and brain injury.Oxidation of KCNB1 Potassium Channels Causes Neurotoxicity and Cognitive Impairment in a Mouse Model of Traumatic Brain Injury.

P2860

Q26849417-3353298F-14CE-4E8E-9C09-4E708F798C59 Q26995622-1096E5B9-33A3-4084-87A1-B229C2BFD494 Q27025923-791FC315-54EB-40A5-80C1-BE463C324B94 Q27667526-06F28A46-C3C1-4D2D-BEB4-2319B87593C4 Q27679012-3090686D-3142-4EC1-ADCF-B56C9286AF9B Q28476479-50E756C2-B2AA-4871-8943-5379C276ACF2 Q28834235-F779131F-246C-4DAB-A018-6720ECAA7A1F Q30393936-B8691470-C9C8-42A8-A008-39A21E70880B Q30417779-5D8BA670-4C7C-4888-A192-92D58E6D68AE Q30516491-2B79AD63-FA42-45F0-9941-F9CE8083E8E0 Q30544943-340F866A-3C82-473D-A6E8-6B9D47643F8F Q33654498-EB7652E9-2541-4FC3-A609-F96AC7B0E0A3 Q33688478-EF096484-C935-41DE-8FF4-BF59E52F6AC9 Q33874259-8758FF80-642A-420B-9F25-C7CEFC1D3086 Q33911283-B1AF0EE3-DA59-4FB1-95FB-B3ADB3B28B7C Q34006977-DC03CFCE-3F91-41A8-B690-876D694300C0 Q34122676-E4C8C9A9-4205-4AB8-ACCB-F95DF41D640E Q34244752-F1D61C98-9C59-4B12-859C-C1B188E8AE28 Q34585992-BFCAB7E6-FCCA-4EB7-A2EB-7C58F0DB1FD5 Q35005059-7710EAFD-B5BB-4E00-919D-2D62FACC48A1 Q35118036-7B6E6127-9AB0-4973-BF19-4A533BAC6185 Q35124699-8FE0E387-EFB9-4C29-AE38-BC04D15BAA90 Q35136572-8286FE5C-B752-47BB-8300-D021BD4A1219 Q35170361-936B868D-F2F1-4336-AB4A-F0D7854A2F2A Q35518170-798EC53F-63C3-4903-8E23-A7D4D3918D62 Q35729506-F17FC069-5BD8-4D2D-9415-08FAC81983DD Q35758331-0A9ED8F0-DD4A-4D0D-B382-19A8CEFCCF44 Q35788820-6CFD7F66-A41F-483E-8333-B8498ECF80BA Q35892864-7C3087D9-91C5-4B4B-AECF-E82AA23D4952 Q35920872-4B451F5C-5585-4EA1-B8E5-840E8B219C0F Q36040645-B9F5C1E9-A667-4DF3-AD06-9A8DD457A206 Q36091270-C1A10B3F-0538-46A3-9C7D-181D11B2F098 Q36128825-E04E5627-DA10-4A0B-B60B-71040F7F4CDF Q36450022-20A941D8-D09F-4282-B0B7-0774AFB34212 Q36600202-DA6384D8-B28E-4ED8-A138-B8D836FF08F1 Q36828224-E923A563-3C5B-4D09-8D23-19D08AA8C54C Q36874745-58FAC038-78B1-4AEF-AA46-84B68F52E701 Q37029561-5B345F8F-C788-4EAB-9F06-4DFED86B5035 Q37091873-4EB67D4E-9EC0-4DA0-96E4-71161E793978 Q37398482-AEB811FA-A0F3-45D0-9477-04B68A9A2C2D

P2860

Targeting protein kinases in central nervous system disorders

http://www.wikidata.org/entity/Q33671660

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Targeting protein kinases in central nervous system disorders

@ast

Targeting protein kinases in central nervous system disorders

@en

type

label

Targeting protein kinases in central nervous system disorders

@ast

Targeting protein kinases in central nervous system disorders

@en

prefLabel

Targeting protein kinases in central nervous system disorders

@ast

Targeting protein kinases in central nervous system disorders

@en

P1433

Q33671660-06DC023A-BD2B-4FF1-8512-E2346854CE2E

P1476

Q33671660-0D734473-57C1-49F7-AB5E-308D6526FB79

P2093

Q33671660-1C338008-FBF5-46FB-B6E6-541A529A0DDC

Q33671660-5B2D3B5D-6C28-45AB-9DC4-1C6632307C93

P2860

Q33671660-0118D220-7459-43E2-BE7B-971FFA021E5A

Q33671660-01D7B628-98EC-4DAC-BD2F-0278DD44D104

Q33671660-02276C0C-433C-4923-8539-DD09DD72B9AA

Q33671660-027FA4AA-DE3F-455C-BA69-278AFA0D2D59

Q33671660-057EDD52-A5DA-42EA-BB52-E1568601EBBD

Q33671660-05BE18A0-C14E-4C01-9AA3-18AB14185DDC

Q33671660-0840F9F2-FE9C-450A-BF5E-72E227F1F210

Q33671660-08A4BF71-3DD1-424F-B53E-6CC68B6B9C79

Q33671660-09684DC1-E06C-4E9B-8E6E-6DBF6EDD7BBC

Q33671660-0A4214DF-4C4B-4EE1-8570-E4885047D147

P2888

Q33671660-41CA29C5-843F-4C05-9724-64486CF94447

P304

Q33671660-3C088A75-259D-4167-ABCD-6D90BE1ADF01

P31

Q33671660-191BDA4C-4299-4EFF-AA01-704F65544159

P356

Q33671660-6222BCEB-E961-400B-994A-FE8025389343

P433

Q33671660-C1AA6AE2-CE30-45CF-B1FD-C34B46FDEFEB

P478

Q33671660-CB1D1305-3A0A-4995-A365-4E8D7CDF9734

P50

Q33671660-64CEF3FC-EF61-4F47-83C2-AA1C54B20C4A

P577

Q33671660-D9F6B147-5BC1-4F6F-BA7C-286BA396257A

P5875

Q33671660-08BA7C46-B50C-47B2-B037-86C634629D45

P6179

Q33671660-ED95524F-9059-4BC2-9D65-E19401B5DCCF

P698

Q33671660-52FD7CA1-B644-4608-B993-4A7094EF39A9

P932

Q33671660-AEAEF24A-15E3-43E8-963F-0F50B1DD0535

P356

P1433

Nature Reviews Drug Discovery

P1476

Targeting protein kinases in central nervous system disorders

@en

P2093

Laura K Chico

http://www.w3.org/2001/XMLSchema#string

Linda J Van Eldik

http://www.w3.org/2001/XMLSchema#string

P2860

Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury

The blood-brain barrier: bottleneck in brain drug development

The death-associated protein kinases: structure, function, and beyond

Ca2+-dependent phosphorylation of syntaxin-1A by the death-associated protein (DAP) kinase regulates its interaction with Munc18

DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy

Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK

A molecular mechanism for the effect of lithium on development

Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics

An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury

P2888

P304

892-909

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD2999

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Daniel Watterson

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38054496

http://www.w3.org/2001/XMLSchema#string

P6179

1008024699

http://www.w3.org/2001/XMLSchema#string

P698

19876042

http://www.w3.org/2001/XMLSchema#string

P932

2825114

http://www.w3.org/2001/XMLSchema#string